StemCell Therapy

Diabetes 22 years
Diabetes side effects include visual impairment, constant urination, shoulder and knee pain. For more information, please contact Physician Peh +65 96266803....

By: Stem Cells

More:
Diabetes 22 years - Video

Diabetes: Progress toward stem cell therapies
California #39;s Stem Cell Agency (CIRM) hosted a live Google Hangout about recent progress in stem cell based strategies for diabetes therapies. The speakers in...

By: California Institute for Regenerative Medicine

Go here to see the original:
Diabetes: Progress toward stem cell therapies - Video

APDF: Stem cells in diabetes -Dr Kumaravel

By: diabetes lecture

Read more:
APDF: Stem cells in diabetes -Dr Kumaravel - Video

Potential Diabetes Breakthrough
HSCI Co-Director Doug Melton and postdoctoral fellow Peng Yi have discovered a hormone that holds promise for a dramatically more effective treatment of type...

By: harvardstemcell

See original here:
Potential Diabetes Breakthrough - Video

Diabetes Precations - Tooth decay Treatment
Diabetes is caused by injury of islet beta; cells of the pancreas, but not organ injury per se. Stem cell transplantation is the very treatment that is most likely to help diabetes patient regenerate the injured islet beta; cells. So stem cell transplantation is an internationally acknowledged treatment for diabetes."

By: Sunil Kumar P

Originally posted here:
Diabetes Precations - Tooth decay Treatment - Video

Diabetes Stem Cell Patient Testimonials
Diabetes Stem Cell Patient TestimonialsFrom:Britanniamed BritanniaViews:0 0ratingsTime:06:46More inScience Technology

Go here to see the original:
Diabetes Stem Cell Patient Testimonials - Video

Targeted Nanoparticle Probes for Embryonic Stem Cell Derived Progenitor Cells
David Larocca. Advanced Cell Technology Inc., Burnham Institute for Medical Research, La Jolla, CA Pluripotent stem cells whether from embryonic (ES) or induced (iPS) cells offer a potentially unlimited source of replacement cells for treating human degenerative diseases associated with aging such as cardiovascular disease, macular degeneration, aging skin, diabetes, Parkinson #39;s, and Alzheimer #39;s disease. The availability of iPS cells will no doubt increase the number of research grade ES-like cell lines dramatically and may ultimately fulfill the need for patient specific stem cells. However, a significant problem and potential bottleneck to developing stem cell therapies is the development of efficient tools and technologies for directed differentiation of pluripotent stem cells toward therapeutic cell types. Currently, this process is poorly understood and often yields differentiated cells that represent only a few percent of the starting ES cells which are difficult to scale up. Identification of surface markers of lineage specific progenitor cells would provide tools for tracking, isolating and scaling these cells to improve differentiation yields and increase our understanding of ES cell differentiation in vitro. Toward this end, we have isolated progenitor cell-targeting peptides by selecting phage display libraries on differentiating ES cells. We have used the cell-targeting peptides or peptide phage themselves to target fluorescent nanoparticles (quantum dots) to ...From:Jeriaska JeriaskaViews:0 0ratingsTime:17:08More inEducation

More here:
Targeted Nanoparticle Probes for Embryonic Stem Cell Derived Progenitor Cells - Video

Lack of funds for a diabetes study is putting at risk work that could place Dunedin at the forefront of stem cell research, University of Otago haematologist and cell biologist Dr Jim Faed says.

In the wake of the global financial crisis, traditional funding sources had "dried up", he said.

Preliminary laboratory work for the stem cell research on diabetes type 1 sufferers at the Spinal Cord Society Research Laboratory has been put on hold.

However, it was hoped public support would get the study back on track and see it start next year, as planned.

Only a few thousand dollars of the $1.8 million needed had been raised, but project leaders were determined to stay positive, he said.

The trial had the potential to find a cure for, or improve the treatment of, diabetes type 1 and other autoimmune diseases.

"This is much bigger than I think many people have realised. We are standing on the brink of huge change in how a number of diseases are going to be treated. I think, in the next few years, we're going to see these diseases tackled effectively."

The trial would build on Chicago research that demonstrated improvement in diabetes type 1 sufferers with use of stem cells from umbilical cords.

Umbilical cord stem cells were shown to increase insulin production in even the most severe diabetics.

The Dunedin study would replicate the study, using stem cell tissue from bone marrow.

Here is the original post:
Diabetes study hit by lack of funds

SACRAMENTO, CA. - A drug used to treat diabetes encourages the brain to grow and repair itself, afinding with far-reaching implications for the treatment of Alzheimers and brain injury, a new study published in Cell: Stem Cell reports.

The widely used diabetes drug metformin comes with the unexpected side effect of causing the growth of new neurons in the brain and makes mice smarter, the July 6th issue of Cell Stem Cell, a Cell Press publication, said. The study has potentially wide-reaching implications for the treatment of Alzheimers in humans and brain related injury.

The discovery has important implications for brain repair because it works not by introducing new stem cells but rather by spurring those that are already present into action, said the study's lead author Freda Miller of the University of Toronto-affiliated Hospital for Sick Children. And since the drug is already so widely used and so safe it means doctors could quickly begin using the drug for brain therapy treatment.

Earlier work by Miller's team highlighted a pathway known as aPKC-CBP for its essential role in telling neural stem cells where and when to differentiate into mature neurons, the report said. Other researchers had found before them that the same pathway is important for the metabolic effects of the drug metformin, but in liver cells.

"We put two and two together," Miller says. If metformin activates the CBP pathway in the liver, they thought, maybe it could also do that in neural stem cells of the brain to encourage brain repairm, he said.

Mice taking metformin not only showed an increase in the birth of new neurons, but they proved to become smarter by being better able to learn the location of a hidden platform in a standard maze test of spatial learning. The new evidence lends support to that promising idea in both mouse brains and human cells.

While it remains to be seen whether the very popular diabetes drug might already be serving as a brain booster for those who are now taking it, there are early hints the drug may have cognitive benefits for people with Alzheimer's disease. Scientists had speculated those improvements were the result of better diabetes control, Miller says, but it now appears that metformin may improve Alzheimer's symptoms by enhancing brain repair.

Miller says they now hope to test whether metformin might help repair the brains of those who have suffered brain injury due to trauma or radiation therapies for cancer.

Original post:
Diabetes drug helps brain growth, makes mice smarter

ScienceDaily (July 5, 2012) The widely used diabetes drug metformin comes with a rather unexpected and alluring side effect: it encourages the growth of new neurons in the brain. The study reported in the July 6th issue of Cell Stem Cell, a Cell Press publication, also finds that those neural effects of the drug also make mice smarter.

The discovery is an important step toward therapies that aim to repair the brain not by introducing new stem cells but rather by spurring those that are already present into action, says the study's lead author Freda Miller of the University of Toronto-affiliated Hospital for Sick Children. The fact that it's a drug that is so widely used and so safe makes the news all that much better.

Earlier work by Miller's team highlighted a pathway known as aPKC-CBP for its essential role in telling neural stem cells where and when to differentiate into mature neurons. As it happened, others had found before them that the same pathway is important for the metabolic effects of the drug metformin, but in liver cells.

"We put two and two together," Miller says. If metformin activates the CBP pathway in the liver, they thought, maybe it could also do that in neural stem cells of the brain to encourage brain repair.

The new evidence lends support to that promising idea in both mouse brains and human cells. Mice taking metformin not only showed an increase in the birth of new neurons, but they were also better able to learn the location of a hidden platform in a standard maze test of spatial learning.

While it remains to be seen whether the very popular diabetes drug might already be serving as a brain booster for those who are now taking it, there are already some early hints that it may have cognitive benefits for people with Alzheimer's disease. It had been thought those improvements were the result of better diabetes control, Miller says, but it now appears that metformin may improve Alzheimer's symptoms by enhancing brain repair.

Miller says they now hope to test whether metformin might help repair the brains of those who have suffered brain injury due to trauma or radiation therapies for cancer.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

Read the original post:
Diabetes drug makes brain cells grow

June 28, 2012

Connie K. Ho for redOrbit.com Your Universe Online

Diabetes is a detrimental disease. In order to combat the illness, University of British Columbia (UBC) researchers conducted a study with an industry partner and discovered that stem cells can reverse Type 1 diabetes in mice.

The discovery leads the way for the development of innovative treatments of diabetes, which is caused by deficient production of insulin by the pancreas. Insulin allows glucose to be held by the bodys muscle, fat, and liver; in turn, its used as fuel for the body. Blindness, heart attack, kidney failure, nerve damage, and stroke are possible consequences of low insulin production. The research by the UBC investigators addressed these various issues. The study was led by Timothy Kieffer, a professor in the Department of Cellular and Physiological Sciences, as well as scientists from BetaLogics, the New Jersey-based division of Janssen Research & Development, LLC.

We are very excited by these findings, but additional research is needed before this approach can be tested clinically in humans, remarked Kieffer, a member of UBCs Life Sciences Institute, in a prepared statement.

The team of investigators is the first to demonstrate that human stem cell transplants can bring back insulin production and reverse diabetes in mice. They were able to re-create the feedback loop that allows insulin levels to automatically increase or decrease based on blood glucose levels. The results from their projects was recently published online on the website of the journal Diabetes.

Following the stem cell transplant, the diabetes mice were slowly taken off insulin, a procedure which was to mirror human clinical condition. Even if they were given copious amounts of sugar, the mice were able to continue healthy blood sugar levels three to four months later. The transplanted cells that were removed from the mice many months after the experiments also showed signs of normal insulin-producing pancreatic cells.

Essentially, the mice were cured of their diabetes by placing the body back in charge of regulated insulin production as it is in healthy, non-diabetics, Kieffer told the Vancouver Sun. It took about four to five months for the [stem] cells to become functional in our experiments and the mice were able to maintain good blood glucose levels even when fed a high-glucose diet, said Kieffer, a UBC professor in the department of cellular and physiological sciences.

Research still needs to be done to finalize details of the approach for diabetes treatment.

The studies were performed in diabetic mice that lacked a properly functioning immune system that would otherwise have rejected the cells. We now need to identify a suitable way of protecting the cells from immune attack so that the transplant can ultimately be performed in the absence of any immunosuppression, explained Kieffer in the statement.

Read the original post:
Diabetes Reversal In Mice Via Stem Cells

Canadian scientists were able to reverse diabetes in mice with a human stem cell transplant, igniting hopes for a cure for the widespread disease -- caused by the failure of the pancreas to produce enough insulin to stabilize blood sugar levels -- in humans.

A paper outlining the work, led by Timothy Kieffer of the University of British Columbia and conducted in partnership with New Jersey-based company BetaLogics, appeared in the journal Diabetes on Tuesday.

Diabetic mice were weaned off of insulin after receiving the pancreatic stem cell transplant, which restarted the cycle in which insulin production rises or falls based on blood sugar levels. Three to four months later, the mice could maintain healthy blood sugar levels even after being fed a lot of sugar.

"We are very excited by these findings, but additional research is needed before this approach can be tested clinically in humans," Kieffer said in a statement on Tuesday.

The researchers cautioned that their study used mice that had a suppressed immune system, the better to prevent rejection of the transplanted cells.

Follow us

"We now need to identify a suitable way of protecting the cells from immune attack so that the transplant can ultimately be performed in the absence of any immunosuppression," Kieffer said.

In 2009, a different team of researchers led by scientists from the University of Sao Paulo in Brazil and Northwestern University reported in the Journal of the American Medical Association that they were able to successfully reverse type 1 diabetes by injecting 8 patients with some of their own stem cells.

Some studies have shown that this kind of stem cell transplantation is only a temporary fix - after anywhere between six months to three years, the insulin-producing cells are again attacked by the patient's immune system.

SOURCE: Rezania et al. "Maturation of Human Embryonic Stem Cell-Derived Pancreatic Progenitors into Functional Islets Capable of Treating Pre-existing Diabetes in Mice." Diabetes 27 June 2012.

Here is the original post:
Diabetes Reversed In Mice Thanks To Stem Cell Transplant

True or false: Type 1 diabetes is only diagnosed in children, and type 2 diabetes only occurs later in life. Although type 1 diabetes used to be known as juvenile diabetes and type 2 was called adult-onset diabetes, the answer is actually false, said Lindsey Elder and Erin Boccia, certified diabetes educators at the Community Diabetes Outreach Services center in Newton, Kan. Not everyone who has type 1 diabetes was diagnosed with the disease as a child, and children can be diagnosed with type 2 diabetes. And while both diseases affect the bodys production of insulin, there are some major differences between the two conditions. Diabetes is a pretty complex disease, Boccia said.

About type 1 diabetes Elder and Boccia said type 1 diabetes is an autoimmune disease. The bodys immune system mistakes insulin-producing cells for foreign invaders, and then attacks and destroys those cells. Those with type 1 diabetes produce little to no natural insulin, and they will need to remain on insulin treatments for the rest of their lives. The onset of type 1 diabetes typically is rather rapid, with symptoms such as frequent urination and extreme thirst. The disease is not preventable and is not impacted by lifestyle choices. Research into pancreas transplants and stem cell treatments have shown some promise.

About type 2 diabetes Most cases of diabetes about 90 to 95 percent are type 2. Unlike type 1 diabetes, this disease develops through insulin resistance rather than insulin destruction. The body continues to produce insulin but doesnt use it efficiently. The insulin-producing cells can lose function gradually over time. Elder and Boccia said type 2 diabetes is impacted by a persons diet and lifestyle choices. Being overweight or obese, particularly in the stomach area, can increase your risk for developing type 2 diabetes, as can a family history of diabetes. Treatment options include managing diet and exercise, oral and injectable medications, and insulin.

Living with diabetes Elder and Boccia said the key to living a healthy, normal life with diabetes is learning as much as you can about your condition. Contact a local diabetes education center, such as the Community Diabetes Outreach Services center in Newton, and find out the best treatment plan for you. Its important to control your blood sugar levels, or complications such as eye and kidney problems can result. Its also important to take an active role in your treatment. Its every day, Boccia said. Its largely a self-managed disease. The doctor cant be with you 24/7 to make those decisions.

Read the original:
Differences between type 1 and 2 diabetes

ScienceDaily (June 27, 2012) University of British Columbia scientists, in collaboration with an industry partner, have successfully reversed diabetes in mice using stem cells, paving the way for a breakthrough treatment for a disease that affects nearly one in four Canadians.

The research by Timothy Kieffer, a professor in the Department of Cellular and Physiological Sciences, and scientists from the New Jersey-based BetaLogics, a division of Janssen Research & Development, LLC, is the first to show that human stem cell transplants can successfully restore insulin production and reverse diabetes in mice. Crucially, they re-created the "feedback loop" that enables insulin levels to automatically rise or fall based on blood glucose levels. The study is published online June 27 in the journal Diabetes.

After the stem cell transplant, the diabetic mice were weaned off insulin, a procedure designed to mimic human clinical conditions. Three to four months later, the mice were able to maintain healthy blood sugar levels even when being fed large quantities of sugar. Transplanted cells removed from the mice after several months had all the markings of normal insulin-producing pancreatic cells.

"We are very excited by these findings, but additional research is needed before this approach can be tested clinically in humans," says Kieffer, a member of UBC's Life Sciences Institute. "The studies were performed in diabetic mice that lacked a properly functioning immune system that would otherwise have rejected the cells. We now need to identify a suitable way of protecting the cells from immune attack so that the transplant can ultimately be performed in the absence of any immunosuppression."

The research was supported by the Canadian Institutes of Health Research, the Stem Cell Network of Canada, Stem Cell Technologies of Vancouver, the JDRF and the Michael Smith Foundation for Health Research.

Diabetes results from insufficient production of insulin by the pancreas. Insulin enables glucose to be stored by the body's muscle, fat and liver and used as fuel; a shortage of insulin leads to high blood sugar that raises the risk of blindness, heart attack, stroke, nerve damage and kidney failure.

Regular injections of insulin are the most common treatment for the type 1 form of this disease, which often strikes young children. Although experimental transplants of healthy pancreatic cells from human donors have shown to be effective, that treatment is severely limited by the availability of donors.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

Read more from the original source:
Diabetes reversed in mice using stem cells

Diabetes currently afflicts approximately 285 million people worldwide, about 6.4 percent of the global population. The World Health Organization projects that this number is set to rise to 366 million by the year 2030.

According to the American Diabetes Association, 1.9 million new cases of diabetes are diagnosed in people aged 20 years and older in 2010, an estimated 7.0 million Americans have undiagnosed diabetes, and another 79 million have pre-diabetes. In addition, approximately 25.8 million children and adults in the United States-8.3% of the population-have diabetes.

Several kinds of treatment for diabetes are currently available, but all of them present specific drawbacks to the patient. For example, insulin therapy can trigger everything from weight gain to hypoglycemia, and its administration must be constantly controlled and monitored by the patient. A novel approach to this problem is currently being pursued by a small biotech company named Orgenesis, which initiated its approach by asking the following question: What if a diabetes patient`s own cells-extracted from his or her own mature tissue-could be made to produce insulin, secreting the compound automatically when needed? This particular variety of cell therapy is a form of what has been dubbed "autologous cell replacement."

For years, the concept of harvesting stem cells and re-implanting them into one`s own body to regenerate organs and tissues has been embraced and researched in animal models. The treatment being developed by Orgenesis consists of several steps. First, a standard liver biopsy is taken from a diabetes patient in a clinical center and sent to a laboratory. In the lab, the liver cells are first propagated in vitro. Some of these cells are then manipulated with a therapeutic agent (i.e., the "master regulator" PDX-1 that governs pancreas development, or additional pancreatic transcription factors in adenovirus-vector) that converts a subpopulation of liver cells into different cells with pancreatic islet phenotype and function.

The therapeutic agent triggers a cascade of events, converting the cells into "autologous insulin-producing" (AIP) cells. These cells now act similarly to the beta cells that produce insulin in the pancreas of healthy individuals. Insulin is not only produced, but also stored and secreted in a glucose-regulated manner.

Back at the clinical center, the newly formed AIP cells are then transplanted in a standard infusion procedure back to the patient`s liver where they secrete insulin. Since the initial liver cells were taken from the patient himself or herself, there is no chance of rejection. Orgenesis has successfully tested its technology in mice, rats and pigs, and is working toward initiating clinical trials in humans.

The surprising capacity to activate pancreatic lineage in the liver was first demonstrated in mice by systemic PDX-1 administration using recombinant adenovirus gene delivery. PDX-1 plays a dual and central role in regulating both pancreas organogenesis in embryo and beta cell function in adults. The capacity of PDX-1 to direct pancreas development has been demonstrated in mature fully differentiated liver in vivo, both in mice and in Xenopus, possibly via a process called trans-differentiation. This describes an irreversible switch of one type of differentiated cell into another differentiated cell. AIP therapy seems to be safer than other options, as it does not alter the host genome but only alters the set of expressed genetic information that seems to be highly specific to the reprogramming protocol. In addition, no human organ donations or embryo-derived cells are required.

This form of therapy, if proven to be workable in clinical trials, would provide several advantages over other insulin-dependent diabetes therapies currently being studied. First, it frees the patient from daily involvement in the monitoring of blood glucose levels, numerous insulin injections and watching food intake and exercise. Indeed, the body itself is now continuously controlling blood glucose levels. In addition to avoiding the chance of autoimmune rejection, the procedure is only minimally invasive.

In summary, the use of adult human liver cells for generating functional insulin-producing tissue may pave the way to autologous implantations, thus allowing the diabetic patient to be the donor of his or her own insulin-producing tissue.

- - - - - - - -

Visit link:
Orgenesis' Sarah Ferber, Ph.D on Using a Diabetes Patient's Own Liver Cells as a Novel Source of Insulin

05-01-2012 12:09 Stem Cell treatments are in the news and sound great. But what is in store for diabetics using them and are they better than a proper diet for diabetes? For this and more information on your diet for diabetes, go to: http://www.dietfordiabetes.ca

The rest is here:
Stem Cell Treatment vs Diet For Diabetes - Video

Not too long ago, George Bush vetoed his first bill after 5, 1/2 years of serving for our country as president. The bill he vetoed did not allow stem cell research to be funded properly by the government, while the many millions of people like me could be cured from the research. His main reasons for vetoing the bill had to do with cloning, and us being a Christian country

More here:
Diabetes - Video

Cellonis Diabetes Stem Cell Therapy: A Chance for Insulin Independence and the Reversal of Complications

BEIJING, June 24 /PRNewswire-Asia/ -- Cellonis, a Beijing and HK-based biotech company, with its new personalized diabetes treatment concept has demonstrated an amazing improvement in their treated patients' conditions. The ongoing clinical study shows the treatment's best case could reconstruct a patient's natural insulin production and even reverse later complications like kidney failure. Treated patients may have the chance to return to the normal activities non-diabetes sufferers take for granted.

The clinical study, jointly conducted by scientists and doctors of the Cellonis clinical research team, aims to help patients be free from insulin and oral drugs, by reconstructing their natural insulin production damaged by either autoimmune disorder (T1DM) or hyperglycemia and also improve insulin sensitivity (T2DM). Using injections of autologous stem cells from the patient's bone marrow, the research team believes that this therapy could help patients return to a life without annoying everyday injections and drugs.

"Most of the patients in our clinical study are now taking less synthetic insulin or oral drugs for BG control," says Dr. Chase Dai, Chief Medical Officer at Cellonis. "We appear to have restored the biological insulin producing function of the body. We are excited to see that some patients have been treatment-free for five months now, and we believe the effect of the stem cell therapy can last much longer. We were also encouraged by some other happy surprises during the clinical study.

"For example, this therapy appears to reverse chronic kidney failure. It was a surprise for all of my team to observe that the kidney function of a 75- year-old patient improved remarkably."

This patient had suffered from diabetes for years, gradually developing diabetic foot and nephropathy. He can now walk freely after having been confined to bed or a wheelchair for six months, and his quality of life has improved significantly. Moreover, he only needs kidney dialysis one time a week instead of three times. In a follow-up visit he excitedly told us that he was hopeful that in the near future he could be completely rid of diabetes.

Diabetes, an increasingly spreading disease, can lead to life-threatening diseases such as blindness, amputation, strokes, or kidney failure in its natural course. Current treatments, including insulin, cannot change this situation.

"We believe that our stem cell therapy will bring promising hope for patients suffering from diabetes and its complications," comments Cindy Hao, CEO of Cellonis. "Personalized diabetes therapies for patients of various conditions will be developed by Cellonis in the near future. We believe what we have restored for patients will not only be their natural insulin production, but also a normal life filled with the activities non-diabetes sufferers can enjoy daily."

Cellonis Biotechnologies focuses on R&D and the clinical application of novel personalized stem cell therapies and immunotherapies for patients with diseases including cancer, diabetes and central nervous system disorders.